Literature DB >> 17139353

The relationships between depression and remission in first-episode psychosis.

Piet Oosthuizen1, Robin Emsley, Dana Niehaus, Liezl Koen, Bonga Chiliza.   

Abstract

This study assessed changes in depressive symptoms over time in 57 patients with first-episode psychosis, and investigated the relationships of these symptoms during the acute psychotic episode and the post-psychotic period with treatment outcome. Assessment instruments included the Calgary Depression Scale (CDS) and the Positive and Negative Syndrome Scale (PANSS). For the evaluation of treatment outcome, recently proposed operational remission criteria were used. PANSS factor analysis identified a depression/anxiety factor (PANSSD/ A) at baseline, which separated into "pure" depression (PANSS-D) and anxiety (PANSS-A) factors at 24 months. There were strong correlations between the CDS and the PANSS-D/A, PANSS-D and PANSS-A scores at baseline, but at 24 months significance was lost between CDS and PANSS-A. Compared to non-remitters, patients who achieved remission had significantly higher baseline CDS scores, but depressive symptoms resolved with antipsychotic treatment. Non-remitting patients had relatively low baseline CDS scores, but their depressive symptoms persisted throughout the study. These findings suggest that depressive symptoms in the acute psychotic episode differ from those in the post-psychotic period in terms of their phenomenology, temporal relationship to psychosis, and treatment response.

Entities:  

Year:  2006        PMID: 17139353      PMCID: PMC1636125     

Source DB:  PubMed          Journal:  World Psychiatry        ISSN: 1723-8617            Impact factor:   49.548


  39 in total

1.  Depression in schizophrenia: recognition and management in the USA.

Authors:  S G Siris; D Addington; J M Azorin; I R Falloon; J Gerlach; S R Hirsch
Journal:  Schizophr Res       Date:  2001-03-01       Impact factor: 4.939

2.  Depressive symptoms at baseline predict fewer negative symptoms at follow-up in patients with first-episode schizophrenia.

Authors:  Piet Oosthuizen; Robin A Emsley; Mimi C Roberts; Jadri Turner; Linda Keyter; Natasha Keyter; Martijn Torreman
Journal:  Schizophr Res       Date:  2002-12-01       Impact factor: 4.939

3.  The nature and prevalence of depression in chronic schizophrenic in-patients.

Authors:  T R Barnes; D A Curson; P F Liddle; M Patel
Journal:  Br J Psychiatry       Date:  1989-04       Impact factor: 9.319

4.  "Akinetic depression" in schizophrenia.

Authors:  T Van Putten; R P May
Journal:  Arch Gen Psychiatry       Date:  1978-09

5.  Targeted treatment of depression-like symptoms in schizophrenia.

Authors:  S G Siris; F Adan; M Cohen; J Mandeli; A Aronson; B Fasano-Dube
Journal:  Psychopharmacol Bull       Date:  1987

6.  Depressive and anxiety symptoms in patients with schizophrenia and schizophreniform disorder.

Authors:  R A Emsley; P P Oosthuizen; A F Joubert; M C Roberts; D J Stein
Journal:  J Clin Psychiatry       Date:  1999-11       Impact factor: 4.384

7.  Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: a double-blind placebo-controlled study.

Authors:  M C Jockers-Scherübl; A Bauer; F Godemann; F M Reischies; F Selig; P Schlattmann
Journal:  Int Clin Psychopharmacol       Date:  2005-01       Impact factor: 1.659

8.  Venlafaxine for the treatment of depressive episode during the course of schizophrenia.

Authors:  Doron Mazeh; Baruch Shahal; Roni Saraf; Yuval Melamed
Journal:  J Clin Psychopharmacol       Date:  2004-12       Impact factor: 3.153

9.  Specificity of the Calgary Depression Scale for schizophrenics.

Authors:  D Addington; J Addington; E Maticka-Tyndale
Journal:  Schizophr Res       Date:  1994-02       Impact factor: 4.939

10.  Validity of the depressive dimension extracted from principal component analysis of the PANSS in drug-free patients with schizophrenia.

Authors:  Meriem El Yazaji; Omar Battas; Mohamed Agoub; Driss Moussaoui; Christel Gutknecht; Jean Dalery; Thierry d'Amato; Mohamed Saoud
Journal:  Schizophr Res       Date:  2002-07-01       Impact factor: 4.939

View more
  7 in total

Review 1.  Elderly patients with schizophrenia and depression: diagnosis and treatment.

Authors:  Kandi Felmet; Sidney Zisook; John W Kasckow
Journal:  Clin Schizophr Relat Psychoses       Date:  2011-01

2.  The serotonin transporter 5-HTTPR polymorphism is associated with current and lifetime depression in persons with chronic psychotic disorders.

Authors:  J Contreras; L Hare; B Camarena; D Glahn; A Dassori; R Medina; S Contreras; M Ramirez; R Armas; R Munoz; R Mendoza; H Raventos; A Ontiveros; H Nicolini; R Palmer; M Escamilla
Journal:  Acta Psychiatr Scand       Date:  2008-11-11       Impact factor: 6.392

3.  Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies.

Authors:  Henry A Nasrallah; Josephine B Cucchiaro; Yongcai Mao; Andrei A Pikalov; Antony D Loebel
Journal:  CNS Spectr       Date:  2014-06-23       Impact factor: 3.790

4.  Treating Depressive Symptoms in Psychosis: A Network Meta-Analysis on the Effects of Non-Verbal Therapies.

Authors:  Laura A Steenhuis; Maaike H Nauta; Claudi L H Bocking; Gerdina H M Pijnenborg
Journal:  PLoS One       Date:  2015-10-20       Impact factor: 3.240

5.  Suicidal behaviour after first-episode psychosis: results from a 1-year longitudinal study in Portugal.

Authors:  Ricardo Coentre; Alexandra Fonseca; Tiago Mendes; Ana Rebelo; Elisabete Fernandes; Pedro Levy; Carlos Góis; Maria Luísa Figueira
Journal:  Ann Gen Psychiatry       Date:  2021-07-06       Impact factor: 3.455

6.  Depressive symptoms in first episode psychosis: a one-year follow-up study.

Authors:  Nasrettin Sönmez; Kristin Lie Romm; Ole A Andreasssen; Ingrid Melle; Jan Ivar Røssberg
Journal:  BMC Psychiatry       Date:  2013-04-05       Impact factor: 3.630

7.  Rimonabant-induced depression in schizophrenia.

Authors:  Rashmi Arasappa; Naren P Rao; Ganesan Venkatasubramanian; Nalini N Reddy; Rishikesh V Behere; Palanimuthu T Sivakumar; Bangalore N Gangadhar
Journal:  Indian J Psychiatry       Date:  2014-04       Impact factor: 1.759

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.